Efficacy of Beremagene Geperpavec in Patients With Dystrophic Epidermolysis Bullosa
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
N. Engl. J. Med 2022 Dec 15;387(24)2211-2219, SV Guide, ME Gonzalez, IS Bağcı, B Agostini, H Chen, G Feeney, M Steimer, B Kapadia, K Sridhar, L Quesada Sanchez, F Gonzalez, M Van Ligten, TJ Parry, S Chitra, LA Kammerman, S Krishnan, MP MarinkovichFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.